Bone loss and inhaled glucocorticoids.

Bone loss and inhaled glucocorticoids.

Detalhes bibliográficos
Principais autores:	van Staa, T, Leufkens, B, Cooper, C
Formato:	Journal article
Idioma:	English
Publicado em:	2002

Registros relacionados

Inhaled corticosteroids and risk of fractures
por: Van Staa, T, et al.
Publicado em: (2000)

Use of inhaled corticosteroids and risk of fractures.
por: van Staa, T, et al.
Publicado em: (2001)

Inhaled corticosteroids and hip fracture: disease or drugs?
por: van Staa, T, et al.
Publicado em: (2003)

Use of inhaled and oral glucocorticoids, severity of inflammatory disease and risk of hip/femur fracture: a population-based case-control study.
por: de Vries, F, et al.
Publicado em: (2007)

Are inhaled corticosteroids associated with an increased risk of fracture in children?
por: van Staa, T, et al.
Publicado em: (2004)

The use of inhaled corticosteroids is not associated with an increased risk of fracture in children.
por: van Staa, T, et al.
Publicado em: (2001)

CUMULATIVE RISKS OF FRACTURE IN PATIENTS USING ORAL GLUCOCORTICOIDS
por: Van Staa, T, et al.
Publicado em: (2004)

Individual fracture risk and the cost-effectiveness of bisphosphonates in patients using oral glucocorticoids.
por: van Staa, T, et al.
Publicado em: (2007)

Fracture risk with intermittent high-dose oral glucocorticoid therapy.
por: De Vries, F, et al.
Publicado em: (2007)

A simple score for estimating the long-term risk of fracture in patients using oral glucocorticoids.
por: van Staa, T, et al.
Publicado em: (2005)

Inhaled corticosteroids and hip fracture: Disease or drugs? [2] (multiple letters)
por: Van Staa, T, et al.
Publicado em: (2003)

Inhaled glucocorticoids and COPD exacerbations.
por: Brightling, C, et al.
Publicado em: (2015)

The value of bone turnover markers in the prediction of vertebral fracture in patients using oral glucocorticoids.
por: van Staa, T, et al.
Publicado em: (2003)

Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy.
por: Van Staa, T, et al.
Publicado em: (2003)

Public health impact of adverse bone effects of oral corticosteroids.
por: van Staa, T, et al.
Publicado em: (2001)

Periarticular bone loss in arthritis: Role of synovial glucocorticoid generation
por: Cooper, MS, et al.
Publicado em: (2010)

Paget's disease of the bone in general clinical practice.
por: van Staa, T, et al.
Publicado em: (2000)

Incidence and natural history of Paget's disease of bone in England and Wales.
por: van Staa, T, et al.
Publicado em: (2002)

Cell Transitions Contribute to Glucocorticoid-Induced Bone Loss
por: Xiaojing Qiao, et al.
Publicado em: (2023-07-01)

Quadrupling inhaled glucocorticoid dose to abort asthma exacerbations
por: McKeever, T, et al.
Publicado em: (2018)

Does a fracture at one site predict later fractures at other sites? A British cohort study.
por: van Staa, T, et al.
Publicado em: (2002)

The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis.
por: van Staa, T, et al.
Publicado em: (2002)

Utility of medical and drug history in fracture risk prediction among men and women.
por: van Staa, T, et al.
Publicado em: (2002)

Use of nonsteroidal anti-inflammatory drugs and risk of fractures.
por: van Staa, T, et al.
Publicado em: (2000)

The estimation of cost-effectiveness thresholds prior to the start of large clinical studies
por: Van Staa, T, et al.
Publicado em: (2006)

Diseases and drugs associated with osteoporosis predict fractures at different sites
por: van Staa, T, et al.
Publicado em: (2001)

Is persistence to bisphosphonate therapy related only to dosing regimen?
por: van Staa, T, et al.
Publicado em: (2006)

Does a fracture at one site predict later fractures at any other site?
por: van Staa, T, et al.
Publicado em: (2001)

The limitations of using simple definitions of glucocorticoid exposure on the prediction of fracture risk
por: Robinson, D, et al.
Publicado em: (2018)

PREDICTORS FOR VERTEBRAL FRACTURES AND FRACTURE THRESHOLD IN PATIENTS USING ORAL GLUCOCORTICOIDS
por: van Staa, T, et al.
Publicado em: (2003)

Inhaled Glucocorticoid Use and the Risk of Osteoporosis in Asthmatic Patients
por: Mojtaba Eizadi, et al.
Publicado em: (2017-11-01)

Glucocorticoid-Induced Bone Loss Is Associated with Abnormal Intravertebral Areal Bone Mineral Density Distribution
por: Louise I. Manning, et al.
Publicado em: (2013-01-01)

Risk of Fracture and Bone Mineral Density in Stroke Response
por: Pouwels, S, et al.
Publicado em: (2010)

The limitations of using simple definitions of glucocorticoid exposure to predict fracture risk: a cohort study
por: Robinson, D, et al.
Publicado em: (2018)

Therapeutic glucocorticoids prevent bone loss but drive muscle wasting when administered in chronic polyarthritis
por: C. G. Fenton, et al.
Publicado em: (2019-08-01)

Glucocorticoids: A review of its adverse effects including bone loss
por: Amit Dua, et al.
Publicado em: (2019-01-01)

Role of glucocorticoid-induced leucine zipper (GILZ) in inflammatory bone loss.
por: Nianlan Yang, et al.
Publicado em: (2017-01-01)

Endogenous Glucocorticoid Metabolism in Bone: Friend or Foe
por: Claire S. Martin, et al.
Publicado em: (2021-08-01)

Individualizing the risks and benefits of postmenopausal hormone therapy.
por: van Staa, T, et al.
Publicado em: (2008)

Epidemiology of fractures in England and Wales.
por: van Staa, T, et al.
Publicado em: (2001)